AAVantgarde Alternatives & Competitors
12 companies similar to AAVantgarde — Pioneering treatments for Stargardt disease and Usher 1B, addressing the root ca...
Companies similar to AAVantgarde
REGENXBIO
Seeking to improve lives through the curative potential of gene therapy.
Rockville, United States
AskBio Inc.
Pioneering science to create transformative molecular medicines.
United States
Spark Therapeutics, Inc.
This company is now integrated into the Roche Group, united in our commitment to do now wh...
Philadelphia, United Stat...
Rocket Pharmaceuticals
Seeking gene therapy cures
Cranbury, United States
Rival Readout
Competing with AAVantgarde? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Ultragenyx
Going Beyond Every Day
Novato, United States
Caribou Biosciences
Clinical-stage biopharmaceutical company developing transformative therapies to treat deva...
Berkeley, United States
GenSight Biologics
Applying pathbreaking science to transform the lives of patients with severe retinal neuro...
Paris, France
Orchard Therapeutics - U.S.
Dedicated to transforming the lives of patients with severe and other genetic diseases thr...
London, United Kingdom
Vivet Therapeutics
Vivet Therapeutics develops gene therapy treatments for inherited liver disorders using li...
Paris, France
ProJenX
ProJenX is a clinical-stage biotech developing novel, brain-penetrant MAP4K inhibitors for...
New York, United States
Emalex Biosciences
Improving people's lives impacted by central nervous system disorders through meaningful s...
Chicago, United States
Exegenesis Bio
We are reimagining ways to develop & manufacture gene therapies. Our mission is to improv...
Philadelphia, United Stat...
About AAVantgarde
AAVantgarde, founded in 2021, is a promising entrant in the biotechnology space, targeting unmet needs in health care. This clinical-stage company is committed to pioneering treatments for Stargardt disease and Usher 1B, with a focus on addressing the root causes of these inherited retinal diseases (IRDs). The company’...
Developing Gene Therapies, Clinical Trial Advancement, Scientific Research and Development
Patients with Inherited Retinal Disorders, Healthcare Providers, Ophthalmologists
Gene Therapy, Inherited Retinal Diseases, Stargardt Disease, Usher Syndrome, AAVantgarde Bio, Clinical Stage Biotechnology, Translational Science, Ophthalmology, Rare Diseases, Retinal Disorders
B2D, B2C, B2B
Product Sales, Service Fee, Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around AAVantgarde: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at AAVantgarde on 28 Jan 2026. The 12 companies listed here were last checked between 11 Jun 2025 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
